Artrya Ltd (ASX: AYA) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Artrya Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.73 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 78.65 million
Earnings per share -0.222
Dividend per share N/A
Year To Date Return -50.00%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Artrya Ltd (ASX: AYA)
    Latest News

    A medical professional uses a tablet showing a digital image of a human body.

    New artificial intelligence ASX share rockets 13% on debut

    Move over Appen, the new AI player in town went gangbusters on its first day as a public company.

    Read more »

    A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
    Technology Shares

    Move over Appen: A new artificial intelligence stock to list on the ASX

    This technology could save some of the 9 million lives lost each year to coronary artery disease.

    Read more »

    Frequently Asked Questions

    No, Artrya has not yet paid dividends to shareholders.

    The company, founded in 2019 in Perth, listed on the ASX on 26 November 2021.

    AYA ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Artrya Ltd

    Artrya Ltd (ASX: AYA) is an AI-driven medical technology company that assists clinicians in the diagnosis of coronary heart disease. Artrya’s Salix Coronary Anatomy is a coronary computed tomography angiography (CCTA) image analysis solution that allows physicians with AI to identify and analyse the extent and type of arterial plaque, and help identify patients at risk of a heart attack.

    The Perth-based company says the technology will revolutionise the speed and accuracy of coronary artery disease diagnosis. The Artrya Ltd share price has steadily declined since the company listed on the ASX in November 2021.

    AYA Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    08 Dec 2023 $0.20 $0.03 17.14% 126,216 $0.18 $0.20 $0.18
    05 Dec 2023 $0.18 $-0.01 -5.56% 50,000 $0.19 $0.19 $0.18
    04 Dec 2023 $0.18 $-0.02 -10.00% 22,430 $0.18 $0.18 $0.18
    01 Dec 2023 $0.20 $0.02 11.11% 80,000 $0.20 $0.20 $0.20
    28 Nov 2023 $0.18 $0.00 0.00% 50,135 $0.18 $0.18 $0.18
    27 Nov 2023 $0.18 $0.00 0.00% 79,538 $0.19 $0.19 $0.18
    24 Nov 2023 $0.18 $-0.02 -10.26% 141,276 $0.20 $0.20 $0.18
    23 Nov 2023 $0.20 $0.01 5.26% 84,438 $0.20 $0.21 $0.19
    22 Nov 2023 $0.19 $-0.02 -9.76% 111,958 $0.21 $0.21 $0.18
    21 Nov 2023 $0.21 $0.00 0.00% 183,513 $0.22 $0.22 $0.21
    20 Nov 2023 $0.20 $-0.01 -4.76% 522,431 $0.23 $0.25 $0.20
    17 Nov 2023 $0.21 $0.01 4.88% 33,543 $0.22 $0.22 $0.21
    14 Nov 2023 $0.21 $-0.03 -12.77% 300 $0.24 $0.24 $0.21
    10 Nov 2023 $0.24 $0.05 26.32% 1,914 $0.24 $0.24 $0.24

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    12 May 2023 Catherine (Kate) Hill Buy 100,000 $25,700
    On-market trade.
    31 Mar 2023 Bernard (Bernie) Ridgeway Buy 300,000 $95,935
    On-market trade.
    06 Mar 2023 Catherine (Kate) Hill Buy 10,312 $3,486
    On-market trade.
    01 Mar 2023 Catherine (Kate) Hill Buy 89,688 $31,095
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Bernard (Bernie) William Ridgeway Non-Executive ChairmanNon-Executive Director Feb 2021
    Mr Ridgeway brings a wealth of corporate experience to Artrya, including 37 years in private and ASX listed companies, spending most of that time in the role of Managing Director. During that time, Imdex's revenue grew from approximately $20m per annum in Australia to more than of $270m per annum, generated from sales from over 100 countries. In that period, the market capitalisation of Imdex grew from below $10m to over $600m, and now exceeds $750m. His vision is for Artrya to become the global standard in non-invasive AI and machine learning to diagnose and treat coronary artery disease.
    Dr Jacque Sokolov Non-Executive Director Aug 2022
    Dr Jacque Sokolov joined the Artrya Board as a Non-Executive Director on 1 August 2022. Dr Sokolov has a experience across all aspects of the US healthcare industry, in particular healthcare delivery, biotechnology, and regulatory clearance. He was appointed Artrya Clinical Advisory Board Chair in January 2022 and Chairman and President of Artrya USA Inc. in March 2022. Dr. Sokolov is Chairman and Chief Executive Officer of SSB Solutions, Inc., a US diversified healthcare management, development, and financial services company. His company has worked with more than 100 healthcare organisations across multiple US healthcare sectors to develop physician-driven, value-focused solutions in rapidly evolving markets
    Ms Catherine (Kate) Hill Non-Executive Director Feb 2023
    Ms Hill has over 20 years' experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately-owned clients. She has worked in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment. She held a variety of leadership and executive roles in Deloitte and served for a period on the Board of Partners of the Australian firm.
    Mr Kevin R Hart Company Secretary Oct 2022
    Kevin R Hart Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No top 20 shareholder's information disclosed 0 0.00%